Authors
David M Simpson, Mark Hallett, Eric J Ashman, Cynthia L Comella, Mark W Green, Gary S Gronseth, Melissa J Armstrong, David Gloss, Sonja Potrebic, Joseph Jankovic, Barbara P Karp, Markus Naumann, Yuen T So, Stuart A Yablon
Publication date
2016/5/10
Journal
Neurology
Volume
86
Issue
19
Pages
1818-1826
Publisher
Lippincott Williams & Wilkins
Description
Objective
To update the 2008 American Academy of Neurology (AAN) guidelines regarding botulinum neurotoxin for blepharospasm, cervical dystonia (CD), headache, and adult spasticity.
Methods
We searched the literature for relevant articles and classified them using 2004 AAN criteria.
Results and recommendations
Blepharospasm: OnabotulinumtoxinA (onaBoNT-A) and incobotulinumtoxinA (incoBoNT-A) are probably effective and should be considered (Level B). AbobotulinumtoxinA (aboBoNT-A) is possibly effective and may be considered (Level C). CD: AboBoNT-A and rimabotulinumtoxinB (rimaBoNT-B) are established as effective and should be offered (Level A), and onaBoNT-A and incoBoNT-A are probably effective and should be considered (Level B). Adult spasticity: AboBoNT-A, incoBoNT-A, and onaBoNT-A are established as effective and should be offered (Level A), and rimaBoNT-B is probably …
Scholar articles
DM Simpson, M Hallett, EJ Ashman, CL Comella… - Neurology, 2016